Breast Cancer · 2024 · 10 citations · 12 references
MedicineOncologyPharmacologyBreast OncologyImmunotherapyMetastasisAdjuvant TherapyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerMetastatic Breast CancerSystemic Therapy For Breast CancerBreast Cancer ChemotherapyGuidanceHer2 ExpressionHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseHuman Epidermal Growth Factor Receptor 2-Targeted TherapyMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast Cancer
The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in breast cancer treatment in Japan. In the recent edition of these guidelines, we addressed a new clinical question 34 (CQ 34, systemic treatment part) "Is trastuzumab deruxtecan recommended for patients with unresectable or metastatic HER2-low breast cancer?" and a new future research question 7 (FRQ 7, pathological diagnosis part) "How is HER2-low breast cancer diagnosed for the indication of trastuzumab deruxtecan?". These questions address use of trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer who have previously received chemotherapy for metastatic disease. The strengths of evidence and recommendation were determined through a quantitative and qualitative systematic review using multiple outcomes, including efficacy and safety. We conclude that trastuzumab deruxtecan is recommended for this patient population (strength of recommendation: 1; strength of evidence: moderate; CQ34) and that HER2-low expression for the indication of trastuzumab deruxtecan should be diagnosed using companion diagnostics based on appropriate criteria (FRQ7).
12
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.5K citations · Full text
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen I. Fernandez, Matthew Liu, Andrew M. Bellizzi et al. · JAMA Oncology · 2022 · 346 citations · Full text